PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
53.82%
Cash & equivalents growing 53.82% while Biotechnology shows decline of -7.27%. Warren Buffett would see this as a competitive advantage in maintaining liquidity while peers face cash constraints.
No Data
No Data available this quarter, please select a different quarter.
53.82%
Below half the Biotechnology median of -5.59% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
54.98%
Below half the Biotechnology median of -5.51%. Jim Chanos would question if the company faces working capital strain.
-8.67%
PP&E growth below half of Biotechnology median of 0.00%. Jim Chanos would suspect potential underinvestment or strategic shift away from core assets.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.00%
≥ 1.5x the Biotechnology median of -0.13%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
53.46%
Below half the Biotechnology median of -4.44%. Jim Chanos might see potential stagnation or distress vs. peers.
21.21%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-57.02%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
37.02%
Below half Biotechnology median of -0.25%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.02%
Below half Biotechnology median of -1.28%. Joel Greenblatt sees a much lower liability expansion vs. peers.
37.77%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-3.87%
0.75-0.9x Biotechnology median of -4.39%. John Neff wonders if the firm lags peers in reinvested profits.
-5.55%
Above 1.5x Biotechnology median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
59.08%
Below half Biotechnology median of -3.91%. Jim Chanos suspects slower net worth growth or losses vs. peers.
53.46%
Below half Biotechnology median of -4.39%. Jim Chanos suspects a major slowdown or distress.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.82%
Below half of Biotechnology median 6.84%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.